HCPLive
OCTOBER 26, 2024
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.
Med Page Today
OCTOBER 26, 2024
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
HCPLive
OCTOBER 26, 2024
VALIANT trial data support pegcetacoplan as the first effective therapy for proteinuria, C3c staining, and eGFR stability in C3G and IC-MPGN patients.
Dr. S. Venkatesan MD
OCTOBER 26, 2024
Here is an attempt for a brief answer that starts with query. 1. The mechanism of LBBB in DCM is 1.Discrete proximal LBBB 2.Diffuse distal LBBB 3. Myocardial LBBB (It is just LBBB morphology due to delayed conduction and not a true LBBB ) 4. It is always a combination of any of the above three Answer :Either 3 or 4 should be the answer I think.It need to be reminded the etiology of cardiomyopathy plays crucial role in determining the cause of LBBB.
HCPLive
OCTOBER 26, 2024
New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.
HCPLive
OCTOBER 26, 2024
The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.
HCPLive
OCTOBER 26, 2024
In this interview, Bunick spoke about the contents of his Fall Clinical Dermatology presentation specifically regarding mechanisms of action and safety of systemic therapies.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
OCTOBER 26, 2024
This interview with Bunick highlighted the Level Up phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.
HCPLive
OCTOBER 26, 2024
Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.
HCPLive
OCTOBER 26, 2024
Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.
HCPLive
OCTOBER 26, 2024
These findings from the phase 3 STRATUM trial suggest significant DLQI score improvements as early as the second week of treatment with roflumilast foam.
HCPLive
OCTOBER 26, 2024
Carla Nester, MD, provides perspective on the results of the VALIANT trial and how it informs the role of pegcetacoplan in C3G and IC-MPGN.
HCPLive
OCTOBER 26, 2024
Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.
Expert insights. Personalized for you.
81 
Let's personalize your content